Brendan P. Teehan's most recent trade in Pacira BioSciences Inc was a trade of 99,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pacira BioSciences Inc | Brendan P. Teehan | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 99,500 | 99,500 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Brendan P. Teehan | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 54,000 | 54,000 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Sale of securities on an exchange or to another person at price $ 16.81 per share. | 17 Nov 2024 | 10,329 | 62,105 (0%) | 0% | 16.8 | 173,630 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 9,913 | 72,434 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 9,913 | 9,913 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 9,913 | 9,913 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 9,913 | 62,521 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 13,629 | 61,711 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Sale of securities on an exchange or to another person at price $ 15.28 per share. | 16 Aug 2024 | 9,534 | 52,177 (0%) | 0% | 15.3 | 145,680 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 5,024 | 48,082 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 6,814 | 20,445 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 6,814 | 45,610 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Sale of securities on an exchange or to another person at price $ 16.94 per share. | 01 May 2024 | 3,477 | 42,133 (0%) | 0% | 16.9 | 58,900 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 5,024 | 10,048 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 5,024 | 41,364 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Sale of securities on an exchange or to another person at price $ 17.87 per share. | 05 Apr 2024 | 2,568 | 38,796 (0%) | 0% | 17.9 | 45,890 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 89,516 | 89,516 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 27,460 | 27,460 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 10,048 | 41,480 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, HEAD OF COMMERCIAL | Sale of securities on an exchange or to another person at price $ 17.90 per share. | 25 Mar 2024 | 5,140 | 36,340 (0%) | 0% | 17.9 | 92,006 | Common Stock |
| Acadia Pharmaceuticals Inc | P. Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 1,107 | 32,056 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | P. Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 1,107 | 1,107 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan Teehan P. | EVP, COO, HEAD OF COMMERCIAL | Sale of securities on an exchange or to another person at price $ 24.67 per share. | 23 Feb 2024 | 624 | 31,432 (0%) | 0% | 24.7 | 15,394 | Common Stock |
| Acadia Pharmaceuticals Inc | Teehan Brendan P. | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 1,287 | 31,680 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 1,287 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | P. Teehan Brendan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 06 Jan 2024 | 731 | 30,949 (0%) | 0% | 30.0 | 21,901 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 14,869 | 39,225 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 14,869 | 24,782 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 14,869 | 24,782 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 17 May 2023 | 14,869 | 24,356 (0%) | 0% | 22.5 | 334,553 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 14,869 | 24,356 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 89,936 | 89,936 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 27,259 | 27,259 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2023 | 1,567 | 10,035 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2023 | 1,567 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 21.18 per share. | 29 Apr 2023 | 548 | 9,487 (0%) | 0% | 21.2 | 11,607 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 5,024 | 15,072 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 5,024 | 10,219 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 05 Apr 2023 | 1,751 | 8,468 (0%) | 0% | 18.2 | 31,798 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 1,107 | 5,656 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 1,107 | 2,214 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 18.78 per share. | 23 Feb 2023 | 461 | 5,195 (0%) | 0% | 18.8 | 8,658 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 1,286 | 5,081 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 1,286 | 1,287 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 1,286 | 2,573 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 17.13 per share. | 06 Jan 2023 | 532 | 4,549 (0%) | 0% | 17.1 | 9,113 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2022 | 1,567 | 1,567 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2022 | 1,567 | 3,989 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 18.18 per share. | 29 Apr 2022 | 552 | 3,437 (0%) | 0% | 18.2 | 10,036 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 68,966 | 68,966 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 20,096 | 20,096 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 1,106 | 3,321 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 1,106 | 2,894 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 23.80 per share. | 23 Feb 2022 | 472 | 2,422 (0%) | 0% | 23.8 | 11,234 | Common Stock |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2022 | 1,286 | 2,573 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2022 | 1,286 | 2,326 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Brendan P. Teehan | EVP, COO, Head of Commercial | Sale of securities on an exchange or to another person at price $ 23.05 per share. | 06 Jan 2022 | 538 | 1,788 (0%) | 0% | 23.1 | 12,401 | Common Stock |